Lyell Immunopharma Q3 net loss widens 17% to $45.53 million

• Lyell Immunopharma’s third-quarter 2026 net loss widened 17% year over year to $45.53 million.
• Research and development expenses rose 45% to $40.9 million, primarily due to increased clinical trial activity.
• An $80 million private placement is expected to extend the cash runway into 2028.
• Ronde-cel pivotal data are expected in mid-2027, with a Biologics License Application submission planned for the second half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041605PRIMZONEFULLFEED9870553) on November 04, 2026, and is solely responsible for the information contained therein.